Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chiba, Urayasu, Japan Clinical Trials

A listing of Chiba, Urayasu, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (53) clinical trials

A Study of LY3435151 in Participants With Solid Tumors

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

Phase

7.35 miles

Learn More »

A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

The primary objective of this trial is: Part A To determine the Maximum tolerated dose (MTD) and/or the recommended dose (RD) of BI 891065 monotherapy for further development in Asian patients with advanced solid tumours Part B To determine the MTD and/or the RD of BI 891065 in combination with ...

Phase

7.35 miles

Learn More »

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).

Phase

7.39 miles

Learn More »

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

The study will be conducted in 2 parts: dose escalation part and dose expansion part. The study will include Pre-treatment Phase, Treatment Phase, and Extension Phase (in dose expansion part only). Eligible participants from Pre-Treatment Phase (screening period) will enter into the Treatment Phase to receive E7386. After Treatment Phase, ...

Phase

7.39 miles

Learn More »

Study of ASP1948 Targeting an Immune Modulatory Receptor in Japanese Patients With Advanced Solid Tumors

This study consists of 2 dose levels (A and B) and enrollment of subjects into dose level A will take place first. Dose level B would only be opened if dose level A is deemed tolerable.

Phase

7.39 miles

Learn More »

A Study of MORAb-202 in Participants With Solid Tumors

The primary objective of this study is to evaluate the tolerability and safety profile of MORAb-202 in participants with solid tumors.

Phase

7.4 miles

Learn More »

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate tolerability of SyB C-0501 in the patients, ...

Phase

7.4 miles

Learn More »

Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies

The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The secondary objective of the study is to assess the immunogenicity of REGN2810.

Phase

7.42 miles

Learn More »

A Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

The primary objective of this study is to evaluate the safety and tolerability of a range of single and 13 repeated doses of BIIB054, administered as intravenous (IV) infusion, in Japanese participants with Parkinson's disease (PD). The secondary objectives are to evaluate the immunogenicity, and serum pharmacokinetics (PK) profile of ...

Phase

8.53 miles

Learn More »

A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm

There are 2 parts to this study for which the primary objectives are to evaluate safety and tolerability, including dose-limiting toxicities (DLTs), and pharmacokinetics of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable ...

Phase

8.53 miles

Learn More »